In Part 5 of this Exclusive Interview from the 2016 Diabetes Symposium in Boston, Dr. Robert Geho explains the potential effect of the proper storage of insulin within the liver on the overall weight of the patient. Robert Geho, MD, is a co-founder and CEO of Diasome Pharmaceuticals, Inc.  In …

In Part 4 of this Exclusive Interview from the 2016 Diabetes Symposium in Boston, understanding the best insulin for the admixture and the possible effect on A1C. Robert Geho, MD, is a co-founder and CEO of Diasome Pharmaceuticals, Inc.  In his role at Diasome, he leads the management and strategic …

In Part 3 of this Exclusive Interview from the 2016 Diabetes Symposium in Boston, Dr. Robert Geho explains the focus on the phase of trials. Robert Geho, MD, is a co-founder and CEO of Diasome Pharmaceuticals, Inc.  In his role at Diasome, he leads the management and strategic direction of …

In Part 2 of this Exclusive Interview from the 2016 Diabetes Symposium in Boston, Dr. Robert Geho explains the effect of insulin on the liver. Robert Geho, MD, is a co-founder and CEO of Diasome Pharmaceuticals, Inc.  In his role at Diasome, he leads the management and strategic direction of …

In Part 1 of this Exclusive Interview, Dr. Robert Geho joins Diabetes in Control publisher Steve Freed at the 2016 Diabetes Symposium in Boston to discuss a new drug delivery system designed to deliver insulin molecules that are currently sold as commercial insulins to cells in the liver. Robert Geho, …

Whenever there is a black box warning on a medication, we have a natural hesitation to use in certain patients. Sometimes these warnings have real consequences, and sometimes they may be related to effects from another older drug in the same class. This was certainly the case with the biguanides, …

Many publications take advantage of videos of Key Opinion Leaders in order to share information with their readers. Most of them will also convert the interview to a transcript. Most times a transcript is good when it is technical knowledge, but there are times when the information is more thought-provoking, …

College student, type 1 diabetes, wears a pump and CGM. She has good family support. Several of her family members get her CGM readings on their phone. She received a call from her mother about 2:45 am waking her up. She told her to treat her low blood glucose, which patient reported to be 41.

In part 3 of this Exclusive Interview about the new diabetes classification, facilitating the individual use of "evidence-based practice" to individually assess the situation of a specific patient, instead of allowing media supposition about a drug class -- such as SGLT-2s -- to dictate diabetes treatment.

In this week's Homerun Slides, ADA guidelines and other special considerations in the treatment of older T2 patients.